Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock and Pre-Funded Warrants

Cibus (Nasdaq: CBUS) announced a proposed underwritten public offering of Class A common stock and pre-funded warrants on March 25, 2026.

Rhea-AI Summary

Cibus (Nasdaq: CBUS) announced a proposed underwritten public offering of Class A common stock and pre-funded warrants on March 25, 2026. The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares offered. Net proceeds are intended for working capital and to fund development of weed management traits in rice. The securities will be offered from an effective Form S-3 shelf registration (File No. 333-273062) and a prospectus supplement will be filed with the SEC. The Offering is subject to market and other conditions and may not be completed.

Positive

• Access to capital for working capital and development
• Proceeds targeted to fund weed management traits in rice
• Offering covered by effective Form S-3 registration

Negative

• Potential shareholder dilution from the offering and pre-funded warrants
• Underwriter option could increase issuance by up to 15%
• Offering completion is uncertain and subject to market conditions

Argus Mar 26 session

-25.78% close to close Open Argus

Details

News Market Reaction – CBUS

On Mar 26, the first trading day after this news, CBUS closed 25.78% below the previous close.

Data tracked by StockTitan Argus for the Mar 26 session.

Market Context

On Mar 26, the first trading day after this news, the stock closed 25.8% below the previous close. A...

Analysis

On Mar 26, the first trading day after this news, the stock closed 25.8% below the previous close. A negative reaction despite a routine financing structure fits prior patterns where offering news often led to selling, with an average move of -10.21% after similar headlines. Historical drawdowns around June 2025 offerings highlight how sensitivity to dilution and funding needs has affected sentiment. Future price behavior could depend on how effectively new capital supports progress in Rice traits and broader programs.

Key Figures

Par value: $0.0001 per share Over-allotment option: 30 days Additional shares option: 15% +4 more

Par value

$0.0001 per share

Class A Common Stock par value in offering

Over-allotment option

30 days

Duration of underwriter option on additional shares

Additional shares option

15%

Underwriter option as % of shares offered

Form S-3 file number

File No. 333-273062

Registration statement referenced for this offering

Shelf filing date

June 30, 2023

Date Form S-3 initially filed with SEC

Amendment date

October 25, 2023

Date Form S-3 was amended

Effectiveness date

October 27, 2023

Date registration statement declared effective

Previous Offering Reports

5 past events · Latest: Jan 29

Same Type 5 events

1. Jan 29

   Offering pricing

   24h Move

   +9.1%

   Priced $20M stock offering at $1.50 with board participation.

2. Jan 28

   Offering proposed

   24h Move

   +9.1%

   Announced proposed underwritten equity offering under existing shelf.

3. Jun 09

   Offering closing

   24h Move

   -0.6%

   Closed $27.5M equity raise at $1.75 per share.

4. Jun 05

   Offering pricing

   24h Move

   -34.3%

   Priced $27.5M stock offering; chairman participated heavily.

5. Jun 04

   Offering proposed

   24h Move

   -34.3%

   Proposed equity raise to fund Rice traits and working capital.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-funded warrants, underwritten public offering, prospectus supplement, base prospectus, +1 more

5 terms

pre-funded warrants financial

"in lieu of common stock to certain investors that so elect, pre-funded warrants to purchase additional shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

"pre-funded warrants to purchase additional shares of its Class A Common Stock in an underwritten public offering"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

prospectus supplement regulatory

"A prospectus supplement describing the terms of the Offering will be filed with the SEC"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

base prospectus regulatory

"pursuant to an effective shelf registration statement on Form S-3 ... including a base prospectus"

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

preliminary prospectus supplement regulatory

"read in their entirety the preliminary prospectus supplement and the accompanying prospectus"

A preliminary prospectus supplement is an initial document that provides important details about a new stock or bond offering before it is finalized. It helps investors understand what is being sold and why, so they can decide whether to invest. Think of it as a preview before the full sales brochure is ready.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 25, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that it intends to offer shares of its Class A common stock, par value $0.0001 per share (“Class A Common Stock”) and, in lieu of common stock to certain investors that so elect, pre-funded warrants to purchase additional shares of its Class A Common Stock in an underwritten public offering (the “Offering”). Cibus also expects to grant to the underwriter of the Offering a 30-day option to purchase up to an additional 15% of the shares of Class A Common Stock offered in the Offering on the same terms and conditions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering.

BTIG, LLC is acting as the sole underwriter for the Offering.

Cibus currently intends to use the net proceeds from the Offering for working capital and general corporate purposes, including to fund further development of its weed management traits in Rice.

The securities will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273062), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 30, 2023, as amended on October 25, 2023, and declared effective by the SEC on October 27, 2023. A prospectus supplement describing the terms of the Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying base prospectus, when available, may be obtained from BTIG, LLC, at 65 East 55th Street, New York, New York 10022 or by telephone at (212) 593-7555, or by email at ProspectusDelivery@btig.com. Before investing in this Offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that Cibus has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about Cibus and such Offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cibus

Cibus is a leader in developing traits (characteristics) that address critical productivity, yield and sustainability challenges. Cibus’ proprietary high-throughput gene editing technologies drive its long-term focus on productivity traits for farmers for the major global row crops. Cibus is not a seed company. It is a technology company that uses its gene editing technologies to develop plant traits at a fraction of the time and cost of conventional breeding and to license them to customers in exchange for royalties.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated Offering and the expected use of the proceeds therefrom. Completion of the Offering is subject to numerous factors, many of which are beyond Cibus’ control, including, without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Cibus does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

CIBUS CONTACTS:

INVESTOR RELATIONS
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com

MEDIA RELATIONS
media@cibus.com

Colin Sanford
colin@bioscribe.com
203-918-4347

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Cibus (CBUS) offering in the March 25, 2026 public offering?

Cibus is offering Class A common stock and pre-funded warrants, with an underwriter option to buy up to 15% additional shares. According to the company, the securities will be sold under an effective Form S-3 shelf registration and described in a forthcoming prospectus supplement.

How will Cibus (CBUS) use the net proceeds from the offering?

Cibus intends to use net proceeds for working capital and further development of weed management traits in rice. According to the company, those uses are specified as general corporate purposes and research development funding.

Who is the underwriter for the Cibus (CBUS) offering and what option do they have?

BTIG, LLC is acting as sole underwriter and may purchase up to an additional 15% of offered shares for 30 days. According to the company, that option is on the same terms and conditions as the Offering.

Is the Cibus (CBUS) offering guaranteed to occur and where are offering documents filed?

The Offering is not guaranteed and is subject to market and other conditions, so completion is uncertain. According to the company, a prospectus supplement will be filed with the SEC and available on the SEC website.

Will the Cibus (CBUS) offering dilute existing shareholders?

Yes, issuance of new shares and pre-funded warrants would dilute existing shareholders if the Offering is completed. According to the company, the underwriter option up to 15% could further increase issued shares and dilution.